An earlier version of this report was published on August 4, 2025. Here’s an update:
The National Cancer Institute (NCI) has launched a more systematic preclinical program to study ivermectin’s ability to kill cancer cells and interact with tumor biology, citing “enough reports” and public interest, but explicitly acknowledging there is still no evidence it works as a cancer treatment in people. See: US Cancer Institute Studying Ivermectin’s ‘Ability To Kill Cancer Cells’
https://kffhealthnews.org/news/article/ivermectin-cancer-treatment-nih-study-dewormer-offlabel-drug/
Commentaries and reviews published in late 2025 emphasize that evidence of anticancer activity remains almost entirely preclinical (cell and animal models) and that there are no large randomized human trials showing benefit. See: Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?
https://pubmed.ncbi.nlm.nih.gov/40715995/
The earlier, richly-footnoted brief report below on ivermectin as a cancer treatment says it shows promise but has not been demonstrated either safe or effective in human clinical trials.